Highlights
- Clinician preference for intensive blood pressure (BP) targets (≤130 mmHg) in older adults is significantly modulated by patient-specific factors, particularly age, frailty status, and a history of falls.
- Digital health monitoring acts as a critical facilitator for treatment intensification, offering a potential solution to overcome clinical inertia in high-risk geriatric populations.
- Latent class analysis identifies two distinct clinician phenotypes: ‘Risk-Tolerant, Digitally Engaged’ (64%) and ‘Risk-Averse’ (36%), highlighting a significant heterogeneity in how evidence-based guidelines are applied in practice.
- While guidelines emphasize intensive control, the actual implementation remains a balance between perceived cardiovascular benefits and the fear of adverse events like syncope or fractures.
Background
Hypertension remains the most prevalent modifiable risk factor for cardiovascular disease (CVD), stroke, and cognitive decline in adults aged 65 and older. Despite robust evidence from landmark trials like SPRINT (Systolic Blood Pressure Intervention Trial) and the STEP (Strategy for Blood Pressure Control in the Elderly Hypertensive Patients) trial, which demonstrated the benefits of intensive systolic blood pressure (SBP) targets (<130 mmHg), clinical implementation in the geriatric population remains inconsistent. This gap between guideline recommendations and bedside practice is often termed “clinical inertia.”
In older adults, the decision to intensify antihypertensive therapy is complicated by concerns regarding polypharmacy, orthostatic hypotension, and the potential for serious adverse events (SAEs) such as falls and acute kidney injury. Clinicians must weigh the long-term benefit of stroke prevention against the immediate risks associated with intensive lowering. Understanding the internal trade-offs and preferences of clinicians is essential for developing interventions that optimize BP management in an aging society.
Key Content
The Evolution of Blood Pressure Targets in the Elderly
Historically, BP targets for older adults were more relaxed. The JNC-8 guidelines (2014) famously recommended a threshold of 150/90 mmHg for those over age 60, citing a lack of evidence for more aggressive targets. However, the publication of the SBP Trial (SPRINT) in 2015 (PMID: 26551272) fundamentally shifted the paradigm. SPRINT demonstrated that an SBP target of <120 mmHg compared to <140 mmHg resulted in a 25% reduction in major cardiovascular events and a 27% reduction in all-cause mortality, even among frail older participants.
Subsequently, the 2017 ACC/AHA guidelines lowered the definition of hypertension to 130/80 mmHg across most age groups (PMID: 29133354). More recently, the STEP trial (2021, PMID: 34459573) confirmed these benefits specifically in an Asian population aged 60–80. Despite this evidence, clinicians often exhibit hesitation when faced with the “oldest old” (those >80 years) or those with significant comorbidities, leading to the current study on clinician preferences.
Methodological Advances: The Discrete Choice Experiment (DCE)
Traditional surveys often fail to capture the nuanced trade-offs clinicians make in real-world settings. The study by O’Hagan et al. (2026) utilized a Discrete Choice Experiment (DCE), a sophisticated quantitative method that requires participants to choose between hypothetical patient profiles. This methodology allows for the estimation of the relative importance of different patient attributes (e.g., age vs. frailty) on the final decision to prescribe intensive treatment.
In this specific DCE involving Australian doctors, hypothetical profiles included variables such as age, frailty (measured by clinical indicators), history of recent falls, residual CVD risk (e.g., high vs. low), and the availability of digital monitoring data (e.g., home BP logs or wearable data).
Key Determinants of Treatment Intensification
The findings from the O’Hagan study (PMID: 41778956) provide a granular look at the hierarchies of clinical decision-making:
- The Threshold of Age: While doctors generally favored intensive targets (OR: 2.70), this preference plummeted as patient age increased. For patients aged 80, the odds of choosing intensive treatment were nearly non-existent (OR: 0.05), suggesting that age remains a primary psychological barrier to guideline adherence, regardless of the patient’s actual vitality.
- Frailty and Falls: Physical vulnerability was a major deterrent. Moderate frailty (OR: 0.24) and a history of recent falls (OR: 0.22) were weighted heavily. Clinicians perceived the risk of an injurious fall as a more immediate threat than a future stroke.
- Digital Health as a Catalyst: Interestingly, the availability of digital health monitoring significantly increased the likelihood of intensifying treatment (OR: 1.50). This suggests that clinicians feel more secure prescribing aggressive doses when they have access to continuous, real-world data to monitor for hypotension or adverse trends.
Clinician Heterogeneity: The Two Faces of Risk
A crucial aspect of this research was the identification of two latent classes of clinicians:
- Class 1: Risk-Tolerant and Digitally Engaged (64%): These clinicians were more likely to follow intensive target evidence and were highly responsive to the presence of digital health tools. They prioritized CVD prevention and felt empowered by data.
- Class 2: Risk-Averse (36%): This significant minority showed no overall preference for intensive targets and were largely unaffected by the provision of digital data. For this group, the fear of treatment-related harm dominated the decision-making process, regardless of the potential cardiovascular benefit.
Expert Commentary
The dichotomy between the “Risk-Tolerant” and “Risk-Averse” clinicians underscores a major challenge in medical education and health policy. Even when guidelines are clear, a third of the workforce may remain hesitant due to a perceived lack of safety margin in the elderly. This highlights that clinical inertia is not merely a failure of knowledge, but a deeply rooted psychological aversion to iatrogenic harm.
The mechanistic rationale for intensive BP lowering—stabilizing the microvasculature and reducing left ventricular hypertrophy—is well-established. However, the biological reality of the aging patient involves reduced baroreflex sensitivity and arterial stiffness, which can lead to larger fluctuations in BP. Digital health tools, as highlighted in this study, serve as a bridge, providing the ‘safety net’ that risk-averse clinicians require to move forward with intensification.
Critics argue that DCEs use hypothetical scenarios that may not perfectly reflect the pressure of a 15-minute consultation. Nevertheless, the alignment of these findings with real-world observational data (where BP control rates drop significantly after age 75) suggests that the DCE accurately mirrors the internal calculations of the modern physician.
Conclusion
Addressing clinical inertia in hypertension management requires more than just publishing new trial results; it requires addressing the specific fears of the clinician. The work by O’Hagan et al. demonstrates that age and frailty are the most significant inhibitors of intensive treatment, while digital health monitoring is a powerful facilitator.
Future research and clinical trials should focus on integrating digital health platforms directly into the clinical workflow to provide the real-time feedback necessary to reassure risk-averse practitioners. Furthermore, guidelines must evolve to provide more explicit instructions on how to manage the ‘oldest old’ and the moderately frail, rather than applying a one-size-fits-all target. By tailoring our approach to both the patient’s biology and the clinician’s psychology, we can more effectively reduce the burden of cardiovascular disease in our aging population.
References
- O’Hagan E, et al. Preferences for Antihypertensive Prescribing in Older Adults: A Discrete Choice Experiment. J Am Coll Cardiol. 2026. PMID: 41778956.
- Wright JT Jr, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control (SPRINT). N Engl J Med. 2015;373(22):2103-2116. PMID: 26551272.
- Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248. PMID: 29133354.
- Zhang W, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP). N Engl J Med. 2021;385(14):1268-1279. PMID: 34459573.
